Focused On-demand Library for Eukaryotic initiation factor 4A-I

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
P60842

UPID:
IF4A1_HUMAN

ALTERNATIVE NAMES:
ATP-dependent RNA helicase eIF4A-1

ALTERNATIVE UPACC:
P60842; B2R6L8; D3DTP9; J3QLC4; P04765; Q5U018; Q61516

BACKGROUND:
The ATP-dependent RNA helicase eIF4A-1, a subunit of the eIF4F complex, is essential for cap recognition and mRNA ribosomal binding. It unwinds RNA secondary structures in the 5'-UTR, a necessary step for the small ribosomal subunit's binding and scanning for the initiator codon, highlighting its pivotal role in translation initiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent RNA helicase eIF4A-1 offers a pathway to novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7376 of 8789